Literature DB >> 1474169

Classifying antiarrhythmic actions: by facts or speculation.

E M Vaughan Williams1.   

Abstract

Classification of antiarrhythmic actions is reviewed in the context of the results of the Cardiac Arrhythmia Suppression Trials, CAST 1 and 2. Six criticisms of the classification recently published (The Sicilian Gambit) are discussed in detail. The alternative classification, when stripped of speculative elements, is shown to be similar to the original classification. Claims that the classification failed to predict the efficacy of antiarrhythmic drugs for the selection of appropriate therapy have been tested by an example. The antiarrhythmic actions of cibenzoline were classified in 1980. A detailed review of confirmatory experiments and clinical trials during the past decade shows that predictions made at the time agree with subsequent results. Classification of the effects drugs actually have on functioning cardiac tissues provides a rational basis for finding the preferred treatment for a particular arrhythmia in accordance with the diagnosis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1474169     DOI: 10.1002/j.1552-4604.1992.tb03797.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  15 in total

1.  QSAR studies on a number of pyrrolidin-2-one antiarrhythmic arylpiperazinyls.

Authors:  Alicja Nowaczyk; Katarzyna Kulig
Journal:  Med Chem Res       Date:  2011-01-07       Impact factor: 1.965

Review 2.  Cardiac ion channels.

Authors:  Birgit T Priest; Jeff S McDermott
Journal:  Channels (Austin)       Date:  2015-08-20       Impact factor: 2.581

3.  Antiarrhythmic drug research.

Authors:  M J A Walker
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

Review 4.  Pharmacologic management of arrhythmias.

Authors:  Leila Ganjehei; Ali Massumi; Alireza Nazeri; Mehdi Razavi
Journal:  Tex Heart Inst J       Date:  2011

Review 5.  Adverse effects of class I antiarrhythmic drugs.

Authors:  J Caron; C Libersa
Journal:  Drug Saf       Date:  1997-07       Impact factor: 5.606

6.  Molecular basis for class Ib anti-arrhythmic inhibition of cardiac sodium channels.

Authors:  Stephan A Pless; Jason D Galpin; Adam Frankel; Christopher A Ahern
Journal:  Nat Commun       Date:  2011-06-14       Impact factor: 14.919

7.  Pharmacogenetics and anti-arrhythmic drug therapy: a theoretical investigation.

Authors:  Colleen E Clancy; Zheng I Zhu; Yoram Rudy
Journal:  Am J Physiol Heart Circ Physiol       Date:  2006-09-22       Impact factor: 4.733

8.  Management of postoperative arrhythmias in pediatric patients.

Authors:  Yaniv Bar-Cohen; Michael J Silka
Journal:  Curr Treat Options Cardiovasc Med       Date:  2012-10

Review 9.  Inhibition of Late Sodium Current as an Innovative Antiarrhythmic Strategy.

Authors:  Philipp Bengel; Shakil Ahmad; Samuel Sossalla
Journal:  Curr Heart Fail Rep       Date:  2017-06

10.  Direct Oral Anticoagulants versus Vitamin K Antagonists in Patients Aged 80 Years and Older.

Authors:  Patrick Manckoundia; Gilles Nuemi; Arthur Hacquin; Didier Menu; Clémentine Rosay; Jérémie Vovelle; Valentine Nuss; Camille Baudin-Senegas; Jérémy Barben; Alain Putot
Journal:  Int J Environ Res Public Health       Date:  2021-04-22       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.